Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2019 18:46 ET | Source: Achaogen, Inc.

Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets

SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug...
April 15, 2019 07:48 ET | Source: Achaogen, Inc.

Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

SOUTH SAN FRANCISCO, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company developing and commercializing innovative antibacterial agents to address...
March 28, 2019 16:01 ET | Source: Achaogen, Inc.

Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting -- -- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic...
March 13, 2019 16:01 ET | Source: Achaogen, Inc.

Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019

SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
February 21, 2019 08:00 ET | Source: Achaogen, Inc.

Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
February 21, 2019 08:00 ET | Source: Achaogen, Inc.

Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine

-- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) -- -- Treatment with ZEMDRI resulted in a greater than four-fold reduction...
February 20, 2019 16:02 ET | Source: Achaogen, Inc.

Achaogen Announces Closing of $15 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
February 20, 2019 16:01 ET | Source: Achaogen, Inc.

Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences

-- Leerink February 27, 2019 at 9:30 a.m. ET -- -- Cowen March 12, 2019 at 12:00 p.m. ET -- SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a...
February 15, 2019 06:11 ET | Source: Achaogen, Inc.

Achaogen Announces Pricing of $15 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...
February 14, 2019 16:00 ET | Source: Achaogen, Inc.

Achaogen Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents...

Next Page keyboard_arrow_right